SLV-324 Treatment of Metastatic Solid Tumors

Summary

This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-324 across a range of dose levels when administered to subjects with metastatic solid tumors.

Timeline

Start

2025-08-25

Primary completion

2027-05

Completion

2027-08

Drugs

Indications